TABLE OF CONTENTS
1 INTRODUCTION 211
1.1 OBJECTIVES OF THE STUDY 211
1.2 MARKET DEFINITION 211
1.3 OVERVIEW OF THE ASIA PACIFIC FAT REDUCTION MARKET 211
1.4 CURRENCY AND PRICING 213
1.5 LIMITATIONS 213
1.6 MARKETS COVERED 214
2 MARKET SEGMENTATION 219
2.1 MARKETS COVERED 219
2.2 GEOGRAPHICAL SCOPE 220
2.3 YEARS CONSIDERED FOR THE STUDY 221
2.4 DBMR TRIPOD DATA VALIDATION MODEL 222
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 225
2.6 MULTIVARIATE MODELLING 226
2.7 TYPE LIFELINE CURVE 226
2.8 DBMR MARKET POSITION GRID 227
2.9 VENDOR SHARE ANALYSIS 228
2.10 MARKET APPLICATION COVERAGE GRID 229
2.11 SECONDARY SOURCES 230
2.12 ASSUMPTIONS 230
3 EXECUTIVE SUMMARY 231
4 PREMIUM INSIGHT 235
4.1 PESTEL ANALYSIS 237
4.2 PORTERS FIVE FORCES 238
4.3 MARKET ANALYSIS 239
4.4 ASIA PACIFIC (PRICING AND PROCEDURE ANALYSIS) 240
4.4.1 JAPAN 240
4.4.2 INDIA 241
4.4.3 CHINA 242
4.4.4 SOUTH KOREA 243
4.4.5 THAILAND 244
4.4.6 MALAYSIA 245
4.4.7 SINGAPORE 246
4.4.8 AUSTRALIA 247
4.4.9 PHILIPPINES 248
4.4.10 TAIWAN 249
4.4.11 INDONESIA 250
4.4.12 NEW ZEALAND 251
4.4.13 VIETNAM 252
4.4.14 PAKISTAN 253
4.4.15 UZBEKISTAN 254
4.4.16 MYANMAR 255
4.4.17 NEPAL 256
4.4.18 COMBODIA 257
4.5 BRAND ANALYSIS 258
4.5.1 KYBELLA 258
4.5.2 AQUALYX 259
4.6 PRICING ANALYSIS (USD) 260
4.6.1 ASIA-PACIFIC 260
4.6.1.1 JAPAN 260
4.6.1.2 INDIA 260
4.6.1.3 CHINA 260
4.6.1.4 SOUTH KOREA 261
4.6.1.5 THAILAND 261
4.6.1.6 MALAYSIA 261
4.6.1.7 SINGAPORE 262
4.6.1.8 AUSTRALIA 262
4.6.1.9 PHILIPPINES 262
4.6.1.10 TAIWAN 263
4.6.1.11 INDONESIA 263
4.6.1.12 NEW ZEALAND 263
4.6.1.13 VIETNAM 264
4.6.1.14 PAKISTAN 264
4.6.1.15 UZBEKISTAN 264
4.6.1.16 MYANMAR 265
4.6.1.17 NEPAL 265
4.6.1.18 COMBODIA 265
4.7 PATENT ANALYSIS OF THE ASIA PACIFIC FAT REDUCTION MARKET 266
4.7.1 JAPAN 266
4.7.1.1 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 266
4.7.1.2 METHOD FOR TREATING ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND ITS SALTS 267
4.7.1.3 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 267
4.7.1.4 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 268
4.7.2 AUSTRALIA 268
4.7.2.1 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF 268
4.7.2.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 269
4.7.3 CHINA 270
4.7.3.1 THE PREPARATION OF DEOXYCHOLIC ACID AND ITS SALT 270
4.7.3.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 270
4.7.3.3 TREATMENT USING DEOXYCHOLIC ACID AND ITS SALT TO THE FAT OF ACCUMULATION 271
4.7.4 INDIA 272
4.7.5 SOUTH KOREA 272
4.8 PRICING ANALYSIS (USD) 273
4.8.1 KYBELLA 273
4.8.2 COOLSCULPTING 275
4.8.3 COOLSCULPTING ELITE 277
4.8.4 COOLTONE 279
5 INDUSTRY INSIGHTS: 282
5.1 DEMOGRAPHIC TRENDS: 283
5.2 CONCLUSION: 284
6 ASIA PACIFIC FAT REDUCTION MARKET, REGULATIONS 285
6.1 JAPAN 285
6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 285
6.1.2 REGULATORY APPROVAL AGENCIES 285
6.1.3 REVIEW, CATEGORIZE, AND PERFORM INGREDIENT ANALYSIS FOR THE AESTHETIC PRODUCT. 285
6.1.4 OBTAINING REQUIRED LICENSES. 286
6.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 286
6.1.6 COSMETIC & QUASI-DRUG MARKETING NOTIFICATION SUBMISSION. 286
6.1.7 IMPORT THE COSMETICS AND QUASI DRUGS INTO JAPAN. 286
6.1.8 PRIMARY DISTRIBUTION APPROVAL 286
6.1.9 COSMETIC MANUFACTURING LICENSE (PACKAGING, LABELING, AND STORAGE). 286
6.2 CHINA 287
6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 287
6.2.2 LICENSING AND REGISTRATION 287
6.2.3 REGULATORY APPROVAL AGENCIES 288
6.2.4 POST-MARKETING SURVEILLANCE 288
6.3 SOUTH KOREA 288
6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
6.3.2 REGULATORY APPROVAL AGENCIES 289
6.3.3 LICENSING AND REGISTRATION 289
6.3.4 POST-MARKETING SURVEILLANCE 289
6.3.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 289
6.4 INDIA 289
6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 289
6.4.2 LICENSING AND REGISTRATION 290
6.4.3 REGULATORY APPROVAL AGENCIES 291
6.4.4 POST-MARKETING SURVEILLANCE 291
6.5 AUSTRALIA 291
6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 291
6.5.2 REGULATORY APPROVAL AGENCIES 292
6.5.3 LICENSING AND REGISTRATION 292
6.5.4 POST-MARKETING SURVEILLANCE 292
6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 292
6.6 SINGAPORE 292
6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 292
6.6.2 REGULATORY APPROVAL AGENCIES 292
6.6.3 LICENSING AND REGISTRATION 293
6.6.4 POST-MARKETING SURVEILLANCE 293
6.6.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 293
6.7 THAILAND 293
6.7.1 THAILAND DRUG REGISTRATION 293
6.7.2 GENERIC DRUG 293
6.8 MALAYSIA 295
6.8.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 295
6.8.2 REGULATORY APPROVAL AGENCIES 295
6.8.3 LICENSING AND REGISTRATION 295
6.8.4 POST-MARKETING SURVEILLANCE 295
6.9 INDONESIA 296
6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 296
6.9.2 REGULATORY APPROVAL AGENCIES 296
6.9.3 LICENSING AND REGISTRATION 296
6.10 PHILIPPINES 296
6.10.1 GET A LICENSE TO OPERATE FROM THE FDA IN THE PHILIPPINES: 297
6.11 NEW ZEALAND 298
6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 298
6.11.2 TIMELINE 298
6.11.3 REGULATORY APPROVAL AGENCIES 298
6.11.4 LICENSING AND REGISTRATION 299
6.11.5 GOOD CLINICAL PRACTICE REQUIREMENTS 299
6.12 TAIWAN 299
6.12.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 299
6.12.2 TIMELINE: 300
6.12.3 REGULATORY APPROVAL AGENCIES 300
6.12.4 POST MARKETING SURVEILLANCE 300
6.13 CAMBODIA 300
6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 300
6.13.2 REGULATORY APPROVAL AGENCIES 302
6.13.3 LICENSING AND REGISTRATION 302
6.13.4 POST-MARKETING SURVEILLANCE 302
6.14 NEPAL 303
6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
6.14.2 REGULATORY APPROVAL AGENCIES 303
6.15 PAKISTAN 303
6.15.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
6.15.2 REGULATORY APPROVAL AGENCIES 303
6.15.3 LICENSING AND REGISTRATION 303
6.16 UZBEKISTAN 304
6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 304
6.16.2 REGULATORY APPROVAL AGENCIES 304
6.16.3 LICENSING AND REGISTRATION 304
6.17 VIETNAM 304
6.17.1 REGULATORY APPROVAL TIMELINE 304
6.17.2 REGULATORY APPROVAL AGENCIES 304
6.17.3 LICENSING AND REGISTRATION 304
7 PIPELINE ANALYSIS OF THE ASIA PACIFIC FAT REDUCTION MARKET 305
8 MARKET ACCESS 312
8.1 MANUFACTURER AND STRATEGIC DEALS 312
8.2 CURRENT TREATMENT PRACTICES 312
8.3 IMPACT OF UPCOMING THERAPY 313
9 MARKET OVERVIEW 314
9.1 DRIVERS 316
9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 316
9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 317
9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 318
9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 319
9.2 RESTRAINTS 320
9.2.1 HIGH COST OF PROCEDURES 320
9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 321
9.2.3 PRODUCT RECALL 321
9.3 OPPORTUNITIES 322
9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 322
9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 323
9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 325
9.4 CHALLENGES 327
9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 327
9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 327
10 ASIA PACIFIC FAT REDUCTION MARKET, BY TYPE 329
10.1 OVERVIEW 330
10.2 SURGICAL FAT REDUCTION 333
10.2.1 LIPOSUCTION 334
10.2.1.1 BY TYPE 335
10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 335
10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 336
10.2.1.1.3 TUMESCENT LIPOSUCTION 336
10.2.1.1.4 SUPER-WET TECHNIQUE 336
10.2.1.2 BY APPLICATION 336
10.2.1.2.1 ABDOMINAL FAT 337
10.2.1.2.2 THIGHS FAT 337
10.2.1.2.3 BUTTOCK FAT 337
10.2.1.2.4 UPPER-ARM FAT 337
10.2.1.2.5 FACIAL FAT-DEPOSITS 337
10.2.1.2.5.1 SUBMENTAL AREAS 338
10.2.1.2.5.2 MALAR 338
10.2.1.2.5.3 MANDIBULAR 338
10.2.1.2.6 KNEE FAT 338
10.2.2 SURGICAL REJUVENATION 338
10.2.2.1 FACE LIFT 339
10.2.2.2 NECK LIFT 339
10.2.3 CHIN IMPLANT 339
10.2.3.1 SILICONE CHIN IMPLANTS 340
10.2.3.2 OTHERS 340
10.2.4 PORUS IMPLANTS 340
10.2.4.1 TEFLON 341
10.2.4.2 GORE-TEX 341
10.2.4.3 MEDPORE IMPLANTS 341
10.3 NON-INVASIVE FAT REDUCTION 341
10.3.1 CRYOLIPOLYSIS 344
10.3.1.1 COOL SCULPTING 344
10.3.1.2 COOL SCULPTING ELITE 344
10.3.1.3 COOL TONE 345
10.3.1.4 OTHERS 345
10.3.1.4.1 ABDOMINAL FAT 345
10.3.1.4.2 THIGHS FAT 345
10.3.1.4.3 BUTTOCK FAT 346
10.3.1.4.4 UPPER-ARM FAT 346
10.3.1.4.5 FACIAL FAT-DEPOSITS 346
10.3.1.4.6 KNEE FAT 346
10.3.2 ULTRASOUND 346
10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 347
10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 347
10.3.2.2.1 ABDOMINAL FAT 348
10.3.2.2.2 THIGHS FAT 348
10.3.2.2.3 BUTTOCK FAT 348
10.3.2.2.4 UPPER-ARM FAT 348
10.3.2.2.5 FACIAL FAT-DEPOSITS 348
10.3.2.2.6 KNEE FAT 348
10.3.3 RADIOFREQUENCY 349
10.3.3.1 ABDOMINAL FAT 349
10.3.3.2 THIGHS FAT 349
10.3.3.3 BUTTOCK FAT 349
10.3.3.4 UPPER-ARM FAT 349
10.3.3.5 FACIAL FAT-DEPOSITS 350
10.3.3.6 KNEE FAT 350

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.